BioCentury | Dec 31, 2020
Distillery Therapeutics

Transcription factor HSF1 as a colon cancer target

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer Inhibiting HSF1, a mediator of the proteotoxic stress response, could treat colorectal cancer induced by chronic inflammation. In colon samples from four colitis-associated colon cancer patients, HSF1 protein levels...
BioCentury | Dec 31, 2020
Distillery Therapeutics

ERR-α identified as target in diabetic and hypertensive kidney disease

DISEASE CATEGORY: Renal INDICATION: Renal damage Promoting expression of the nuclear receptor ERR-α could treat kidney disease associated with diabetes and hypertension. Levels of ERR-α mRNA  were lower in microdissected human kidney samples samples from patients...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one...
BioCentury | Nov 10, 2020
Product Development

First biomarker data from pioneering tau program in Alzheimer’s cloud use of antibodies for the target

Data presented at the annual CTAD meeting hint that anti-tau therapy semorinemab from Genentech and AC Immune may have engaged its target yet failed to decrease tau aggregation in a Phase II study to treat...
BioCentury | Nov 5, 2020
Product Development

FDA signals relatively clear path ahead for Alzheimer’s therapy aducanumab

FDA appears to be leaning toward approval of the first theoretically disease-modifying therapy for Alzheimer’s disease, or any neurodegenerative disorder, based on two incomplete Phase III trials, one...
BioCentury | Oct 3, 2020
Translation in Brief

A SARS-CoV-2 genome degrader; neutralizing influenza B mAbs; Fulcrum’s sickle cell therapy increases fetal hemoglobin and more

Matt Disney’s small molecule RNA degraders for COVID-19A Scripps Research team led by Expansion Therapeutics Inc. founder Matthew Disney published an ACS Central Science study describing a small molecule that binds a SARS-CoV-2 hairpin RNA structure that...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Small molecule kinase inhibitor for cystic fibrosis with splicing mutation

DISEASE CATEGORY: Pulmonary INDICATION: Cystic fibrosis (CF) A small molecule inhibitor of four kinases that regulate splicing could treat CF caused by the most common disease-associated CFTR splicing...
BioCentury | Sep 29, 2020
Product Development

Alzheimer milestones & vaccine politics: a BioCentury podcast

Alzheimer’s disease therapies continue to tease and torment biotech investors. In the latest BioCentury This Week podcast, BioCentury editors discuss the road ahead for Biogen’s closely watched therapy aducanumab and anti-tau therapies, whose most significant...
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

The Phase II miss of the first tau antibody to reach that stage continue the tradition in Alzheimer’s disease of bad news with hard-to-interpret ramifications for the target. At a minimum, the data call into...
BioCentury | Sep 5, 2020
Translation in Brief

Matt Disney’s microRNA-targeting angiogenesis compound; Arrakis’ platform to find compounds’ RNA targets; dual target CAR Ts for HIV and more

Scripps microRNA-targeted VEGF-A stimulatorA Scripps Research Institute team led by Matthew Disney has designed a compound that targets a  precursor of miR-377, a direct inhibitor of angiogenesis...
Items per page:
1 - 10 of 3519